KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.278
+0.003 (1.13%)
At close: Mar 6, 2026, 4:00 PM EST
0.288
+0.010 (3.63%)
After-hours: Mar 6, 2026, 7:57 PM EST
KALA BIO Employees
KALA BIO had 38 employees as of December 31, 2024. The number of employees decreased by 5 or -11.63% compared to the previous year.
Employees
38
Change (1Y)
-5
Growth (1Y)
-11.63%
Revenue / Employee
n/a
Profits / Employee
-$943,184
Market Cap
7.86M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| Bolt Biotherapeutics | 40 |
| Kiora Pharmaceuticals | 12 |
| Iterum Therapeutics | 9 |
| Alzamend Neuro | 7 |
| Ernexa Therapeutics | 6 |
| PharmaCyte Biotech | 2 |
| Addex Therapeutics | 2 |
KALA News
- 3 days ago - KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” - GlobeNewsWire
- 2 months ago - KALA BIO Settles Approximately $10.6 million of Debt - GlobeNewsWire
- 3 months ago - KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
- 7 months ago - KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 8 months ago - KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - GlobeNewsWire
- 10 months ago - KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewsWire